Skip to main content
Gout
Disease State Hub
Menu
Menu
Main navigation
Home
Education
Featured Diseases & Conditions
Acute Hepatic Porphyria
Alzheimer Disease
COVID-19
Depression Care 360
Diabetes Technology
Digital Health Solutions in Diabetes
HER2-Positive Early Breast Cancer
HIV Management
Neuromyelitis Optica Spectrum Disorder
Primary Hyperoxaluria
Ulcerative Colitis
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Multidisciplinary Roundtables
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Association of Neurological Surgeons Annual Meeting
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
Society of Gynecologic Oncology Annual Meeting
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Job Board
Search
Contact
Login
Menu
Menu
Main navigation
Home
Education
Featured Diseases & Conditions
Acute Hepatic Porphyria
Alzheimer Disease
COVID-19
Depression Care 360
Diabetes Technology
Digital Health Solutions in Diabetes
HER2-Positive Early Breast Cancer
HIV Management
Neuromyelitis Optica Spectrum Disorder
Primary Hyperoxaluria
Ulcerative Colitis
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Multidisciplinary Roundtables
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Association of Neurological Surgeons Annual Meeting
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
Society of Gynecologic Oncology Annual Meeting
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Job Board
Advertisement
Treatment
Pop Quiz: ACR Guideline on the Treatment of Gout
Copied to clipboard
<section><h2><p>Despite recommendations from the American College of Rheumatology (ACR) and other international societies, the use of treat‐to‐target strategies with urate‐lowering therapy (ULT) has not increased over the past 20 years. To encourage more adherence to ULT for treating patients with gout, the ACR updated its guidelines to provide stronger evidence in favor of ULT as the preferred therapeutic agent. Which of the following agents does the ACR recommend for first-line therapy for patients with gout?</p></h2></section><section><h2><p>Despite recommendations from the American College of Rheumatology (ACR) and other international societies, the use of treat‐to‐target strategies with urate‐lowering therapy (ULT) has not increased over the past 20 years. To encourage more adherence to ULT for treating patients with gout, the ACR updated its guidelines to provide stronger evidence in favor of ULT as the preferred therapeutic agent. Which of the following agents does the ACR recommend for first-line therapy for patients with gout?</p></h2></section><section><h2><p>Better luck next time</p></h2></section><section><h3><p>Nice job!</p></h3></section>
advertisement
Advertisement
Advertisement
